



ASX RELEASE

21 April 2009

Dear Shareholder

1:14 Non Renounceable Rights Issue Offer

This letter is to notify you that on 21 April 2009, ChemGenex Pharmaceuticals Limited (**ChemGenex**) lodged a Rights Issue Cleansing Notice and accompanying Information Booklet with ASX for a 1:14 non-renounceable rights issue of ordinary shares in ChemGenex. This issue will raise approximately \$7.4 million (**Offer**), and follows on from the recent Placement to sophisticated and institutional investors which raised \$10 million.

ABN AMRO Morgans Corporate Limited has agreed to Underwrite \$5 million under the Offer.

Shareholders are being offered one (1) new ordinary share in ChemGenex for every fourteen (14) existing shares held at an issue price of \$0.43 per share.

The Rights Issue Cleansing Notice and accompanying Information Booklet will be despatched to shareholders on 4 May 2009. Copies of the Rights Issue Cleansing Notice and Information Booklet (**Offer Documents**) are available for review on ASX's website, www.asx.com.au, as well as on the ChemGenex website www.chemgenex.com.

These Offer Documents are important and will require your immediate attention.

Use of proceeds

The purpose of the Offer is to raise funds primarily to:

- complete clinical development and regulatory filings in the US and Europe for omacetaxine in respect of the T315I indication
- further progress discussions with pharmaceutical companies to secure distribution partners for omacetaxine outside of the US
- prepare for the commercial launch of omacetaxine in the US

Important dates

Event	Date
Announcement of the Offer and lodgement of notice in accordance with section 708AA Corporations Act	21 April 2009
Ex Date	23 April 2009
Record Date for determining entitlements (7.00 pm AEST)	29 April 2009
Despatch of Information Booklet and Entitlement and Acceptance Form	4 May 2009
Closing Date (5.00 pm AEDST)	22 May 2009
Company notifies ASX of under subscriptions	27 May 2009
Allotment and issue of New Shares and lodgement of cleansing notice in accordance with section 708A Corporations Act	28 May 2009
Despatch of holding statements in respect of New Shares	29 May 2009
Trading of New Shares expected to commence on ASX	29 May 2009

This offer closes at 5pm (AEDST) on 22 May 2009.

Non-renounceable pro rata issue

The new shares issued under the Prospectus will rank equally with the ordinary shares currently on issue.

Eligible shareholders may take up their entitlement in full or in part. Your entitlement will be determined as at 7pm (AEDST) on 29 April 2009, being the Record Date. Applications can be made only in accordance with personalised Entitlement and Acceptance Form which shareholders will receive with the Offer Documents.

Fractional entitlements to shares are rounded up to the nearest whole number of shares. Your entitlement is shown in the personalised Entitlement and Acceptance Form accompanying the Offer Documents.

The rights issue is non-renounceable. Rights may not be traded.

Overseas holders

The offer of shares under the Offer Documents is limited to eligible shareholders with registered addresses in Australia or New Zealand. With the exception of New Zealand shareholders, overseas shareholders will not be offered new shares.

To date Shareholders have shown great loyalty to ChemGenex and I believe you will see the merit in supporting this major fundraising initiative.

Your Board of Directors commends this offer of new shares for your consideration.

Yours sincerely



Brett Heading
Chairman